Evidence map›Paper›PMID 36578580›Full record

ArticleFrontiers in microbiology2022

Yinchen Linggui Zhugan decoction ameliorates high fat diet-induced nonalcoholic fatty liver disease by modulation of SIRT1/Nrf2 signaling pathway and gut microbiota.

Hui Jiang, Tangyou Mao, Zhongmei Sun, Lei Shi, Xiao Han, Yang Zhang, Xiaosi Zhang, Jiali Wang, Juncong Hu, Liming Zhang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. SIRT1 in Liver Diseases: Mechanistic Insights and Therapeutic Prospects.International journal of biological sciences · 2025
    Review
  7. Review
  8. Review
  9. Review
  10. Vitamin D improves hepatic steatosis in NAFLDFrontiers in endocrinology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Hui JiangSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Tangyou MaoDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Zhongmei SunSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Lei ShiDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Xiao HanSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Yang ZhangSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Xiaosi ZhangSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Jiali WangSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Juncong HuSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Liming ZhangSchool of Graduate, Beijing University of Chinese Medicine, Beijing, China.
Junxiang LiDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Haixiao HanDongfang Hospital, Beijing University of Chinese Medicine, Beijing, China.
Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Yinchen Linggui Zhugan decoction (YLZD) is an effective and classical traditional herbal prescription for treating the nonalcoholic fatty liver disease (NAFLD) and has been proven to be effective in the regulation of lipid metabolism disorder and attenuate inflammation for a NAFLD rat model. However, the exact underlying mechanism has not been elucidated. In the current study, a NAFLD rat model was established using a high-fat diet (HFD) for 10 weeks, followed by YLZD treatment with 1.92 g/kg/day for 4 weeks to explore the mechanisms of YLZD. Our results showed that YLZD decreased the hepatic lipid deposition, restored the liver tissue pathological lesions, inhibited the expression of oxidative stress, and decreased the inflammatory cytokines levels. Meanwhile, the genes and proteins expressions of SIRT1/Nrf2 signaling pathway together with downstream factors including HO-1 and NQO1 were elevated in the YLZD treated NAFLD rats. For further elaborating the upstream mechanism, short-chain fatty acids (SCFAs) in serum and feces were measured by liquid chromatograph mass spectrometer and gas chromatograph mass spectrometer, and the differences in gut microbiota of rats in each group were analyzed through high-throughput sequencing of 16S rRNA. The results demonstrated that the contents of butyric acid (BA) and total SCFAs in YLZD-treated NAFLD rats were significantly increased in serum and feces. 16S rRNA sequencing analysis illustrated that YLZD intervention led to a modification of the gut microbiota composition, with a decrease of

Indexed as

gut microbiotametabolitesnonalcoholic fatty liver diseaseshort-chain fatty acidsspearman rank correlation analysisYinchen Linggui Zhugan decoction

Identifiers

PMID36578580
PMCPMC9791106
OpenAlexW4312123565

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.